

Thursday, November 12, 2026

See page X for oral and moderated e-poster presentations

Hall A – ART/IVF/Infertility

13:00-14:30	DO WE TRUST MEDICAL PUBLICATIONS?	HALL D
Capsule	Are clinical activity and scientific evidence mutually exclusive? Huxley: Facts do not stop existing even if we don't know or deny their existence	
Chairpersons	Bart Fauser , <i>Netherlands</i> Zion Ben Rafael , <i>Israel</i>	
13:00-13:15	FMM : Why we keep using fetal heart rate monitoring -an unproven technology that is associated with high CS rate and its related complications Giuseppe Rizzo , <i>Italy</i>	
13:15-13:20	Discussion	
13:20-13:35	IVF : Ovulation stimulation - Do we trust scientific evidence? Enrico Papaleo , <i>Italy</i>	
13:35-13:40	Discussion	
13:40-13:55	GYNECOLOGY : Endometriosis: Enucleation of endometriomas can lead to ovarian failure - should we not operate until completion of family planning? Jacques Donnez , <i>Belgium</i>	
13:55-14:00	Discussion	
14:00-14:15	GENETICS : PGT-A: Lack of trust in evidence, ignorance, or just ignoring it? Sebastiaan Mastenbroek , <i>Netherlands</i>	
14:15-14:20	Discussion	
14:20-14:30	General Discussion	

14:30-15:30	INTEGRITY IN SCIENCE	HALL D
Capsule	COGI continues this educational series by examining the escalating “paper mill” crisis in scientific publishing. Notably, fraudulent authors were registered and later proposed as reviewers, and it took two years to uncover the forgery network. The peer-review process is also becoming increasingly challenging.	
Chairpersons	Basil Tarlatzis , <i>Greece</i> Laura Rienzi , <i>Italy</i>	
14:30-14:45	Peer review process is deteriorating: Where to go from here - Can AI assist or replace reviewers? Edgardo Somigliana , <i>Italy</i>	
14:45-14:50	Discussion	
14:50-15:05	Peer review is in peril: What can we do about it? Catherine Racowsky , <i>France</i>	
15:05-15:10	Discussion	
15:10-15:25	How to reduce research waste: What can scientists, universities and funding bodies do about it Bart Fauser , <i>Netherlands</i>	
15:25-15:30	Discussion	
15:30-16:00	Coffee break	

16:00-17:00	OBESITY: RISK DURING DIFFERENT PHASES OF LIFE	HALL D
Capsule	Obesity can reduce ovulation, leading to hormonal imbalance, and increased complications and comorbidities affecting fertility, pregnancy and menopause. Now that we have effective treatment why not use it for all?	
Chairpersons	Joop Laven , <i>Netherlands</i> Zion Ben Rafael , <i>Israel</i>	
16:00-16:15	Should we counsel patients to lose weight before pregnancy? What are the risks of obesity during pregnancy and labor Yariv Yogev , <i>Israel</i>	
16:15-16:20	Discussion	
16:20-16:35	Personalized obesity care: Translating new insights into practical treatment strategies, including pharmacotherapy Elisabeth van Rossum , <i>Netherlands (virtual)</i>	
16:35-16:40	Discussion	
16:40-16:55	GLP-1 medications before fertility treatment: Game changer or costly delay? Vasiliki A. Moragianni , <i>USA</i>	
16:55-17:00	Discussion	

17:00-18:30	WHAT IS NEW IN OUR FIELD?	HALL D
-------------	---------------------------	--------

Capsule	In vitro gene editing was performed successful, but also illegally, Techniques that can cure a baby or embryos from lethal disease are probably welcome but the road to abuse remains widely open Also, slowing the ovarian clock is an achievable goal?
Chairpersons	Sebastiaan Mastenbroek , <i>Netherlands</i> Catherine Racowsky , <i>France</i>
17:00-17:15	Futuristic gene editing for polygenic diseases Shai Carmi , <i>Israel</i>
17:15-17:20	Discussion
17:20-17:40	Slowing the ovarian clock: mTOR inhibition and the future of menopause Zev Williams , <i>USA</i>
17:40-17:45	Discussion
17:45-18:05	Judging follicle/oocyte maturity only by follicular ultrasound phenotype Norbert Gleicher , <i>USA</i>
18:05-18:10	Discussion
18:10-18:25	Finding the unfindable: AI-based rare sperm recovery and the redefinition of Azoospermia Zev Williams , <i>USA</i>
18:25-18:30	Discussion

18:30-19:30	OPENING SESSION	HALL D
Chairpersons	Zion Ben Rafael , <i>Israel</i> Bart Fauser , <i>Netherlands</i> Rita Vassena , <i>Spain</i>	
18:30-18:35	Introduction Rita Vassena , <i>Spain</i>	
18:35-19:20	<i>Keynote lecture in honor of Nobel Prize Laureate Robert G. Edwards</i> How oocyte vitrification has impacted ART: History, efficiency, and utilization nowadays Ana Cobo , <i>Spain</i>	
19:20-19:30	Young Scientist Best Abstract Award Presented by Rene Frydman , <i>France</i> and Zion Ben Rafael , <i>Israel</i>	
19:30-20:30	<i>Networking Reception in the exhibition area</i>	

Hall B

14:30-17:30	INDUSTRY SUPPORTED COURSE <i>See page X</i>	HALL B
--------------------	---	---------------

Hall C

09:00-14:00	PRACTICAL WORKSHOP OF INTRAPARTUM ULTRASOUND <i>*Pre-registration required</i>	HALL C
Background	Intrapartum emergencies require a prompt and efficient intervention by labor ward multiprofessional team. Ultrasound have been recently suggested as a valuable and objective tool which may assist the clinician in the diagnosis and the management of the labor complications and lead eventually to an improved outcome. The main aim of this course is to present the role of ultrasound in the management of abnormal labor providing the labor ward team with all the basic theoretical and practical knowledge which are complimentary to the clinical skills and may optimise the final outcome. This course is performed with the use of a dedicated mannequin which has been developed for the sonographic training in transperineal ultrasound.	
Course facilitators	Giuseppe Rizzo , <i>Rome, Italy</i> Ilenia Mappa , <i>Rome, Italy</i> Valentina Tsibizova , <i>Perugia, Italy</i>	
09:00-09:30	Welcome	
09:30-10:00	Ultrasound in labor: Why and how? Giuseppe Rizzo , <i>Italy</i>	
10:00-10:30	Ultrasonographic diagnosis of labor arrest Ilenia Mappa , <i>Italy</i>	
10:30-11:00	US and operative vaginal delivery Giuseppe Rizzo , <i>Italy</i>	
11:00-11:30	<i>Coffee Break</i>	
11:30-12:00	The role of simulators in obstetrical ultrasound Valentina Tsibizova , <i>Italy</i>	
12:00-13:30	Hands-on simulation LaborSIM- OpusLab with the mannequin Supervised by the faculty	
13:30-14:00	Closing remarks	

Friday, November 13, 2026

Hall A – ART/IVF/Infertility

08:30-10:00	ARTIFICIAL INTELLIGENCE (AI)	HALL A
Capsule	Could artificial intelligence take over aspects of clinical management in ART?	
Chairpersons	Frank Broekmans , <i>Netherlands</i> Efstratios Kolibianakis , <i>Greece</i>	
08:30-09:00	Debate: Any place for AI in ovulation induction?	
08:30	Yes: Konstantinos Dafopoulos , <i>Greece</i>	
08:40	No: Charalampos Siristatidis , <i>Greece</i>	
08:50	Discussion	
09:00-09:15	New developments in the use of AI for ovarian stimulation Vasiliki A. Moragianni , <i>USA</i>	
09:15-09:20	Discussion	
09:20-09:35	Day 3 compared to day 5 Raoul Orvieto , <i>Israel</i>	
09:35-09:40	Discussion	
09:40-09:55	Deep learning versus manual morphology-based embryo selection in IVF: Results of the largest published RCT Christos Venetis , <i>Greece</i>	
09:55-10:00	Discussion	
10:00-10:30	<i>Coffee break, visit the exhibition and e-poster viewing</i>	
10:30-12:00	SURPRISE ME WITH..... UNEXPECTED SOLUTIONS...	HALL A
Capsule	Hot controversial clinical issues	
Chairpersons	Jacques Donnez , <i>Belgium</i> Paul Pirtea , <i>France</i>	
10:30-10:45	The surprising results of the optimal follicular size before trigger: What AI reveals? Simon Hanassab , <i>UK</i>	
10:45-10:50	Discussion	
10:50-11:20	Debate: Stem cells or surgery for Asherman Syndrome?	
10:50	Operation, even in extreme cases is the solution - what are the limits? Ettore Cicinelli , <i>Italy</i>	
11:00	Stem cells for endometrial regeneration: Xavier Santamaria , <i>Spain</i>	
11:10	Discussion	
11:20-11:35	Double trigger compared to IVM Raoul Orvieto , <i>Israel</i>	
11:35-11:40	Discussion	
11:40-11:55	Istmocoele: Reasons and treatment Ettore Cicinelli , <i>Italy</i>	
11:55-12:00	Discussion	
12:00-12:05	<i>Change of session</i>	
12:05-12:30	PLENARY SESSION	HALL A <i>Streamed to Hall D & E</i>
Capsule	PCOS is the most common endocrinopathy that affect all phases of women's life	
Chairpersons	Bart Fauser , <i>Netherlands</i> Joop Laven , <i>Netherlands</i>	
12:05-12:25	PCOS in OBGYN (overview of PCO in reproductive life, menopause, pregnancy etc) Terhi Piltonen , <i>Finland</i>	
12:25-12:30	Discussion	
12:30-12:35	<i>Change of session</i>	
12:35-13:35	INDUSTRY SUPPORTED SESSION <i>See page X</i>	HALL B
12:35-13:05	INDUSTRY SUPPORTED SESSION <i>See page X</i>	HALL C
13:35-14:30	<i>Lunch break, visit the exhibition and e-poster viewing</i>	
14:30-15:30	IMPLANTATION FAILURE	HALL A
Capsule	RIF: Aneuploidy is the main reason, while all other reasons are infrequent and correctable	
Chairpersons	Zion Ben Rafael , <i>Israel</i> Edgardo Somigliana , <i>Italy</i>	

14:30-14:40	Ethnic disparities in IVF success, implications to treatment personalization Simon Hanassab, UK
14:40-14:45	Discussion
14:45-15:15	Debate: What is the origin of implantation failure?
14:45	Euploidy is crucial and is age-dependent: Paul Pirtea, France
14:55	Euploidy is not enough for implantation: Antonis Makrigiannakis, Greece
15:05	Discussion
15:15-15:25	Immunological factor - Endometrial profiling and LBR (RCT) Efstratios Kolibianakis, Greece
15:25-15:30	Discussion
15:30-15:35	<i>Change of session</i>
15:35-17:00	SIMPLE LESS EXPENSIVE IVF? HALL A
Capsule	Should we adopt more simple, affordable IVF and prevent expensive, additional unproven add-ons?
Chairpersons	Basil Tarlatzis, Greece Konstantinos Zikopoulos, Greece
15:35-15:50	Modern IVF settings: Is the cost rising while the chances are falling? Norbert Gleicher, USA
15:50-15:55	Discussion
15:55-16:10	Low-resource setting, high IVF results: From scientific validation to global reproductive justice Willem Ombelet, Belgium
16:10-16:15	Discussion
16:15-16:35	After how many IVF failures should we adopt add-ons? Edgardo Somigliana, Italy
16:35-16:40	Discussion
16:40-16:55	Progestin-based ovarian stimulation vs, GnRh analogues Paul Pirtea, France
16:55-17:00	Discussion
17:00-17:20	<i>Coffee break, visit the exhibition and e-poster viewing</i>
17:20-18:30	MANAGEMENT OF UTERINE FIBROIDS HALL A
Capsule	Fibroids that distort the uterine cavity are likely to affect fertility however the effect of non-cavity distorting intramural fibroids on fertility is still debated. Does their presence lower the chance of achieving a live birth?
Chairpersons	Ettore Cicinelli, Italy George L. Adonakis, Greece
17:20-17:40	Debate: Intramural fibroids should be enucleated before IVF
17:20	Yes: Nikolaos Vlachos, Greece
17:25	No: Antonis Makrigiannakis, Greece
17:30	Discussion
17:40-17:55	Hysteroscopic management of submucous fibroids: Techniques and limitations Grigoris F. Grimbizis, Greece
17:55-18:10	Which fibroids should be removed and how before IVF? Angelos Daniilidis, Greece
18:10-18:25	REAdME - Fertility-limiting diseases of the pelvic organs and their influence on endometrial cavity receptivity Michal Mára, Czech Republic
18:25-18:30	Discussion

Friday, November 13, 2026

Hall B – Embryology

08:30-10:00	AI AND AUTOMATION IN IVF LABORATORY	HALL B
Capsule	A recent RCT by Illingworth et al et al (Nature Medicine 2024) was unable to demonstrate non-inferiority of a deep learning algorithm compared with standard morphology. Although no harm in using AI selection was proven, AI -based solutions need to demonstrate improvement in time, quality, and safety in IVF laboratory procedures, without compromising clinical outcomes, while reducing cost, before widespread adoption	
Chairpersons	Miguel Gallardo Molina , Portugal Rita Vassena , Spain	
08:30-09:00	Debate: Does AI improve embryo selection in IVF	
08:30	Pro: AI can improve embryo selection Giovanni Coticchio , Italy	
08:40	Con: RCTs are lacking and without clear proofs, it should not be adopted Alessandro Bartolacci , Italy	
08:50	Discussion	
09:00-09:25	AI in sperm selection: Difficult cases and proxy molecular markers Ioannis Sfontouris , Greece	
09:25-09:30	Discussion	
09:30-09:55	Automation in lab work in IVF - how far did we get? Do we still need an embryologist? Laura Rienzi , Italy	
09:55-10:00	Discussion	
10:00-10:30	Coffee break, visit the exhibition and e-poster viewing	
10:30-12:00	VITRIFICATION	HALL B
Capsule	Shorter vitrification and warming protocols are becoming more common for embryos, while still lagging somewhat behind oocytes. New approaches are being considered that challenge our understanding of cryobiology, and new media are being developed to improve results.	
Chairpersons	Helen Picton , UK Laura Rienzi , Italy	
10:30-10:55	Shorter protocols of vitrification and warming: The science behind the models Miguel Gallardo Molina , Portugal	
10:55-11:00	Discussion	
11:00-11:25	Simplified vitrification and warming: Clinical validation and implementation in practice Ana Cobo , Spain	
11:25-11:30	Discussion	
11:30-11:55	Is direct warming of embryos the new revolution? Rita Vassena , Spain	
11:55-12:00	Discussion	
12:00-12:05	Change of session	
12:05-12:30	PLENARY SESSION	HALL A Streamed to Hall D & E
Capsule	PCOS is the most common endocrinopathy that affect all phases of women's life	
Chairpersons	Bart Fauser , Netherlands Joop Laven , Netherlands	
12:05-12:25	PCOS in OBGYN (overview of PCO in reproductive life, menopause, pregnancy etc) Terhi Piltonen , Finland	
12:25-12:30	Discussion	
12:30-12:35	Change of session	
12:35-13:35	INDUSTRY SUPPORTED SESSION See page X	HALL B
12:35-13:05	INDUSTRY SUPPORTED SESSION See page X	HALL C
13:35-14:30	Lunch break, visit the exhibition and e-poster viewing	

14:30-15:30	IVM AND IMMATURE OOCYTES	HALL B
Capsule	In vitro maturation has by now proven safe and effective on a per-oocyte basis, although clinical adoption seems to be lagging. The efficiency of controlled ovarian hyperstimulation however, clashes with the comfort of patients and the increase in cost of the procedure (drugs, anesthetic services, recovery time, etc..). Is there a place for true IVM in standard clinical practice?	
Chairpersons	Alessandro Bartolacci, Italy Ioannis Sfontouris, Greece	
14:30-15:00	Debate: This house believes that “true” IVM should be part of the toolkit of every clinic	
14:30	Pro: IVM should be indicated for certain patients Leonidas Zepeiridis, Greece	
14:40	Con: IVM cannot rival OHSs in cumulative efficiency and should not be proposed George Lainas, Greece	
14:50	Discussion	
15:00-15:25	In vitro derived oocytes: From research to clinical application Helen Picton, UK	
15:25-15:30	Discussion	
15:30-15:35	<i>Change of session</i>	
15:35-17:00	QUO VADIS PGT-A?	HALL B
Capsule	In spite of the clear results from 2 non-selection studies, some questions still persist in the PGT-A world. We are debating advances and limitations of this technology, and look at future developments in the field. PGT-P for polygenic is a controversial technique that uses scores to estimate embryos risk to develop adults diseases like diabetes to select those with lower risk	
Chairpersons	Helen Picton, UK Giovanni Coticchio, Italy	
15:35-16:05	Debate: Should we report mosaicism in PGT-A?	
15:35	Yes, we should: Darren Griffin, UK	
15:45	No, we should not: Alessandro Bartolacci, Italy	
15:55	Discussion	
16:05-16:25	When PGT-M is needed, should we test also for aneuploidy Sebastiaan Mastenbroek, Netherlands	
16:25-16:30	Discussion	
16:30-16:55	PGT-P: The future of PGT or an unethical approach? Shai Carmi, Israel	
16:55-17:00	Discussion	
17:00-17:20	<i>Coffee break, visit the exhibition and e-poster viewing</i>	
17:20-18:30	AN EMBRYO IS AN EMBRYO IS AN EMBRYO?	HALL B
Capsule	From choosing the best day to transfer to the developmental potential of nonconventional fertilized oocytes, this session will challenge some long held beliefs and present new evidence for	
Chairpersons	Rita Vassena, Spain Mina Popovic, Spain	
17:20-17:40	1PN, 2.1PN, 3PN: when to rescue and when to discard? Laura Rienzi, Italy	
17:40-18:00	Are embryos better nurtured in utero or in vitro? A comparison of day 3 vs day 5 transfer, including a cost-effectiveness perspective Giovanni Coticchio, Italy	
18:00-18:20	How to care for the embryo in challenging laboratory settings Catherine Racowsky, France	
18:20-18:30	Q&A	

Friday, November 13, 2026

Hall C - Gynecology

08:30-10:00	SURGERY IN ENDOMETRIOSIS AND ADENOMYOSIS	HALL C
Capsule	Endometriosis and adenomyosis - when to treat, when to operate and when not	
Chairpersons	Theodoros Theodoridis, Greece Athanasios Protopapas, Greece	
08:30-08:50	Decoding the mechanisms of endometriosis-related infertility Jacques Donnez, Belgium	
08:50-08:55	Discussion	
08:55-09:10	Endometriosis and infertility: When to operate and how? Grigoris F. Grimbizis, Greece	
09:10-09:15	Discussion	
09:15-09:25	Adenomyosis and IVF outcomes Eileen Manalo, Philippines	
09:25-09:30	Discussion	
09:30-09:45	Adenomyosis should be operated on before pregnancy George Pistofidis, Greece	
09:45-10:00	Adenomyosis: From organoid model to medical therapy Marie-Madeleine Dolmans, Belgium	
10:00-10:30	Coffee break, visit the exhibition and e-poster viewing	

ALL ABOUT BACK TO PRESCRIBING HRT

After 20 years, the WHO has removed the black box warning from HRT. The following session will address this topic.

10:30-12:00	OPTIMISING LONG TERM MENOPAUSE HEALTH	HALL C
Capsule	Focusing on strategies for optimising long-term health and quality of life during menopause	
Chairpersons	TBA Nick Panay, UK	
10:30-10:45	Menopause and work ability - gaps and solutions Terhi Piltonen, Finland	
10:45-10:50	Discussion	
10:50-11:05	Optimising quality of life after gynecological cancer Alessandra Graziottin, Italy	
11:05-11:10	Discussion	
11:10-11:40	Debate: Should HRT be prescribed in asymptomatic natural menopause?	
11:10	For: Mark Brincat, Malta	
11:20	Against: Angelica Hirschberg, Sweden	
11:30	Discussion	
11:40-11:55	Laser for the GSM in breast cancer survivors Zdenko Vižintin, Slovenia	
11:55-12:00	Discussion	
12:00-12:05	Change of session	

12:05-12:30	PLENARY SESSION	HALL A Streamed to Hall D & E	to
Capsule	PCOS is the most common endocrinopathy that affect all phases of women’s life		
Chairpersons	Bart Fauser, Netherlands Joop Laven, Netherlands		
12:05-12:25	PCOS in OBGYN (overview of PCO in reproductive life, menopause, pregnancy etc) Terhi Piltonen, Finland		
12:25-12:30	Discussion		
12:30-12:35	Change of session		

12:35-13:35	INDUSTRY SUPPORTED SESSION	HALL B
	See page X	

12:35-13:05	INDUSTRY SUPPORTED SESSION	HALL C
	See page X	

13:35-14:30 Lunch break, visit the exhibition and e-poster viewing

14:30-15:30	MENOPAUSE SYMPTOMS - GENESIS, IMPLICATIONS AND MANAGEMENT	HALL C
Capsule	Exploring the genetic origins, neurological mechanisms, and practical clinical management of menopausal symptoms like vasomotor symptoms and vulvovaginal atrophy	
Chairpersons	Alessandra Graziottin , <i>Italy</i> George L. Adonakis , <i>Greece</i>	
14:30-14:45	Genetic determinism of menopause: SIG genetics at IMS Micheline Misrahi , <i>France</i>	
14:45-14:50	Discussion	
14:50-15:05	VMS, peripheral or central nervous system? Mark Brincat , <i>Malta</i>	
15:05-15:10	Discussion	
15:10-15:25	Practical management strategies of Vasomotor Symptoms (VMS) and Vulvovaginal Atrophy (VVA) in the menopausal transition Dimitrios Goulis , <i>Greece</i>	
15:25-15:30	Discussion	

15:30-15:35 Change of session

15:35-17:00	HORMONE DEPENDENT DISORDERS IN PRE AND PERI MENOPAUSAL WOMEN	HALL C
Capsule	Addresses the management, long-term cardiometabolic impacts, and pregnancy implications of hormone-dependent disorders like PCOS/PMOS (Polyendocrine Metabolic Ovarian Syndrome) and premenstrual syndromes, and initiating HRT during pre- and perimenopause	
Chairpersons	Basil Tarlatzis , <i>Greece</i> Dimitrios Goulis , <i>Greece</i>	
15:35-15:45	Managing severe premenstrual disorders especially in perimenopause Nick Panay , <i>UK</i>	
15:45-15:50	Discussion	
15:50-16:10	PCOS/PMOS - long-term cardiometabolic implications Bart Fauser , <i>Netherlands</i>	
16:10-16:15	Discussion	
16:15-16:25	Recurrent pregnancy loss in Polycystic Ovary Syndrome: Underlying genetic and metabolic contributors Elene Asanidze , <i>Georgia</i>	
16:25-16:30	Discussion	
16:30-17:00	Debate: Should HRT be started in pre/peri menopausal women?	
16:30	For: Nick Panay , <i>UK</i>	
16:40	Against: Angelica Hirschberg , <i>Sweden</i>	
16:50	Discussion	

17:00-17:20 Coffee break, visit the exhibition and e-poster viewing

17:20-18:30	POI AND EARLY MENOPAUSE	HALL C
Chairpersons	Nick Panay , <i>UK</i> Micheline Misrahi , <i>France</i>	
17:20-17:35	Premature ovarian aging: Genetic causes, fertility prognosis, and health consequences Micheline Misrahi , <i>France</i>	
17:35-17:50	Ovarian function ceases way before other organs start to fail; lessons learned from DNA testing? Joop Laven , <i>Netherlands</i>	
17:50-18:05	Is early menopause a different entity from POI? Panagiotis Anagnostis , <i>Greece</i>	
18:05-18:30	Debate: Routine use of PRP & stem cells in POI?	
18:05	For: Pietro Molinaro , <i>Italy</i>	
18:10	Against: Basil Tarlatzis , <i>Greece</i>	
18:15	Discussion	

Friday, November 13, 2026

Hall D – Fetomaternal Medicine

08:30-10:00	CONTROVERSIES IN TWINS	HALL D
Chairpersons	Asma Khalil, UK Nir Melamed, Canada	
08:30-08:45	Should we use twin-specific growth charts or singleton charts to diagnose growth restriction? Asma Khalil, UK	
08:45-09:00	Should progesterone and steroids be used in twins with a short cervix? Nir Melamed, Canada	
09:00-09:30	Debate: Does cerclage help or harm in twin pregnancies with cervical shortening?	
09:00	Pro: Andrew Shennan, UK	
09:10	Con: Liran Hirsch, Israel	
09:20	Discussion	
09:30-10:00	Debate: Should we suggest fetal reduction in Bichorionic/Biamniotic (BC/BA) twins	
09:30	Pro: Yariv Yogev, Israel	
09:40	Con: Eyal Sheiner, Israel	
09:50	Discussion	
10:00-10:30	Coffee break, visit the exhibition and e-poster viewing	

10:30-12:00	IUGR - INTRAUTERINE GROWTH RESTRICTION	HALL D
Chairpersons	Apostolos Athanasiadis, Greece Nir Melamed, Canada	
10:30-11:00	Debate: Estimated Fetal Weight (EFW) 3rd percentile, normal doppler indices. When to deliver 36? 37? 38? Later?	
10:30	Pro: Nir Melamed, Canada	
10:40	Con: Asma Khalil, UK	
10:50	Discussion	
11:00-11:30	Debate: Can we prevent the recurrence of fetal growth restriction (FGR)? Is there a role for aspirin? Low Molecular Weight Heparin (LMWH)? Pravastatin?	
11:00	Pro: Liran Hirsch, Israel	
11:10	Con: Amir Aviram, Canada	
11:20	Discussion	
11:30-11:45	Testing the placenta in pregnancies with FGR - black box or crystal ball? What to ask the pathologist? How it guides for future treatment? Anastasia Konstantinidou, Greece	
11:45-12:00	Nutrition, supplementation and toxic nutrients in pregnancy: How to integrate our knowledge for better pregnancy outcome? Gian Carlo Di Renzo, Italy	
12:00-12:05	Change of session	

12:05-12:30	PLENARY SESSION	HALL A Streamed to Hall D & E
Capsule	PCOS is the most common endocrinopathy that affect all phases of women's life	
Chairpersons	Bart Fauser, Netherlands Joop Laven, Netherlands	
12:05-12:25	PCOS in OBGYN (overview of PCO in reproductive life, menopause, pregnancy etc) Terhi Piltonen, Finland	
12:25-12:30	Discussion	
12:30-12:35	Change of session	

12:35-13:35	INDUSTRY SUPPORTED SESSION	HALL B
	See page X	
12:35-13:05	INDUSTRY SUPPORTED SESSION	HALL C
	See page X	

13:35-14:30	Lunch break, visit the exhibition and e-poster viewing	
-------------	--	--

14:30-15:30	LARGE FOR GESTATIONAL AGE (LGA) - BEING LARGE IS NOT SO SIMPLE	HALL D
Chairpersons	Asma Khalil, UK Howard Berger, Canada	
14:30-14:45	Can we accurately predict macrosomia? The use of AI Giuseppe Rizzo, Italy	
14:45-15:05	Debate: What is the optimal timing and mode of delivery in cases of suspected LGA/macrosomia? Should we offer induction of labor (IOL)?	
14:45	Pro: Emmanuel Attali, Israel	
14:50	Con: Asma Khalil, UK	
14:55	Discussion	
15:05-15:30	Debate: Should we perform late third trimester oral glucose tolerance test (OGTT) in cases of suspected LGA	
15:05	Pro: Yariv Yogev, Israel	
15:10	Con: Howard Berger, Canada	
15:15	Discussion	
15:30-15:35	Change of session	
15:35-17:00	CONTROVERSIES AROUND PROM AND PPROM (PRETERM AND TERM PRELABOR RUPTURE OF MEMBRANES)	HALL D
Chairpersons	Liran Hiersch, Israel Apostolos Mamopoulos, Greece	
15:35-16:00	Debate: Should all women with PPROM receive antenatal corticosteroids at presentation?	
15:35	Pro: Nir Melamed, Canada	
15:40	Con: Gerard Visser, Netherlands	
15:45	Discussion	
16:00-16:20	Debate: PPROM with cerclage: To remove or not to remove? If yes when? After completion of corticosteroids	
16:00	Pro: Yariv Yogev, Israel	
16:05	Con: Amir Aviram, Canada	
16:10	Discussion	
16:20-16:40	Debate: Should tocolysis be used in PPROM to allow steroid administration?	
16:20	Pro: George Daskalakis, Greece	
16:25	Con: Themistoklis Dagklis, Greece	
16:30	Discussion	
16:40-17:00	Debate: Immediate delivery vs expectant management in PROM between 34 and 37 weeks	
16:40	Pro: Apostolos Athanasiadis, Greece	
16:45	Con: Apostolos Mamopoulos, Greece	
16:50	Discussion	
17:00-17:20	Coffee break, visit the exhibition and e-poster viewing	
17:20-18:35	FROM PREDICTION TO PREVENTION IN OBSTETRICS	HALL D
Chairpersons	Asma Khalil, UK Apostolos Athanasiadis, Greece	
17:20-17:40	Debate: Should we provide aspirin for all?	
17:20	Pro: Amir Aviram, Canada	
17:25	Con: Ioannis Tsakiridis, Greece	
17:30	Discussion	
17:40-18:00	Debate: Metformin for the obese gravida at early pregnancy?	
17:40	Pro: Emmanuel Attali, Israel	
17:45	Con: Dimitrios Goulis, Greece	
17:50	Discussion	
18:00-18:20	Debate: Tubectomy at cesarean section for risk reduction of ovarian cancer?	
18:00	Pro: Rinat Gabbay-Benziv, Israel	
18:05	Con: Nikolaos Thomakos, Greece	
18:10	Discussion	
18:20-18:35	Preparing OB practice for a warmer world Tamar Wainstock, Israel	

Saturday, November 14, 2026

Hall A – ART/IVF/Infertility

08:30-10:00	PMOS - THE NEW PCOS	HALL A
Capsule	It is important to get the new name promoted and implemented	
Chairpersons	Bart Fauser , <i>Netherlands</i> Basil Tarlatzis , <i>Greece</i>	
08:30-08:55	Name change: Patients perspective Rachel Morman , <i>UK</i>	
08:55-09:00	Discussion	
09:00-09:25	Name change: The health care providers perspective Terhi Piltonen , <i>Finland</i>	
09:25-09:30	Discussion	
09:30-09:55	Polyendocrine Metabolic Ovarian Syndrome (PMOS): The new Polycystic Ovarian Syndrome (PCOS): Dissemination and next steps Joop Laven , <i>Netherlands</i>	
09:55-10:00	Discussion	

10:00-10:30 *Coffee break, visit the exhibition and e-poster viewing*

10:30-12:00	PGT-A	HALL A
Capsule	An ASRM statement, grounded in over 30 years of experience and multiple randomized controlled trials demonstrating no clinical improvement in IVF outcomes with the use of PGT-A, nevertheless PGT-A sharply increase in utilization	
Chairpersons	Norbert Gleicher , <i>USA</i> Laura Rienzi , <i>Italy</i>	
10:30-10:45	The cost-effectiveness of re-biopsy and post-cryopreservation biopsy in PGT-A cycles Alessandro Bartolacci Error! Bookmark not defined. , <i>Italy</i>	
10:45-10:50	Discussion	
10:50-11:20	Debate: Claims of lower miscarriage rate and speed up of the time to pregnancy with PGT-A	
10:50	Pro: This justifies the cost and utilization of PGT-A! Christos Venetis , <i>Greece</i>	
11:00	Con: Only if we don't trust the RCTs showing no effect of PGT-A? Mina Popovic , <i>Spain</i>	
11:10	Discussion	
11:20-11:35	Invasive vs noninvasive PGT-A - from cell DNA to cell - free DNA Dimitris Loutradis , <i>Greece</i>	
11:35-11:40	Discussion	
11:40-11:55	Is there a potential legal danger for physicians to be sued for performing PGT-A? Norbert Gleicher , <i>USA</i>	
11:55-12:00	Discussion	

12:00-12:05 *Change of session*

12:05-12:30	PLENARY SESSION	HALL A <i>Streamed to Hall D & E</i>
Capsule	Epigenetics and reprogramming research in infertility and in utero development focuses on how DNA methylation, histone modification, and RNA interact during gametogenesis, early embryogenesis and placentation, disruption of which causes infertility and pregnancy complications	
Chairpersons	Rene Frydman , <i>France</i> Mina Popovic , <i>Spain</i>	
12:05-12:25	Epigenetics and reprogramming David Monk , <i>UK</i>	
12:25-12:30	Discussion	

12:30-13:30 *Lunch break, visit the exhibition and e-poster viewing*

13:30-15:00	Q & A	HALL A
Capsule	Experts' views on controversial and unsolved clinical and laboratory questions	
Chairpersons	Zion Ben Rafael , <i>Israel</i> Bart Fauser , <i>Netherlands</i>	
Discussants	Laura Rienzi , <i>Italy</i>	

Rita Vassena, Spain
Paul Pirtea, France
Basil Tarlatzis, Greece

Questions to the panel

Embryology

- Sperm separation and selection techniques: Do any really improve embryo quality and outcomes?
- Should time-lapse imaging be implemented for all ART cycles?
- Should genetic carrier screening be proposed systematically before ART?
- Is non-invasive PGT-A still a promising approach?
- Does the number of laser pulses impact embryo biopsy

Clinical aspects of IVF

- Rescue IVM; Is it clinically relevant
- Could artificial intelligence take over aspects of clinical management in ART?
- Does recurrent implantation failure still exist as a distinct entity?
- How can we decrease the cost of IVF, is natural IVF still useful in current practice?
- Is preeclampsia truly more frequent after artificial embryo transfer cycles?

Mild ovarian stimulation for patients with diminished ovarian reserve: myth or reality?

15:00-16:30	OVARIAN STIMULATION	HALL A
Capsule	Basic issues in ovulation stimulation are still not resolved	
Chairpersons	Zion Ben Rafael, Israel Konstantinos Dafopoulos, Greece	
15:00-15:30	Personalization of ovarian stimulation, do we need to base it on age and Markers of ORT Frank Broekmans, Netherlands	
15:30-16:00	Debate: How important is the choice of gonadotropins and monitoring during stimulation?	
15:30	It is important: Evangelos Makrakis, Greece	
15:40	No better results were proven: Ioannis E. Messinis, Greece	
15:50	Discussion	
16:00-16:30	Debate: Mild ovarian stimulation for patients with diminished ovarian reserve (DOR): Myth or reality?	
16:00	Higher doses will increase oocyte yield Frank Broekmans, Netherlands	
16:10	Mild stimulation is the right way Paul Pirtea, France	
16:20	Discussion	

Saturday, November 14, 2026

Hall C – Gynecology

08:30-10:00	NOVEL HORMONAL AND NON-HORMONAL APPROACHES IN MENOPAUSE	HALL C
Capsule	Prescribing HRT is back what are the new therapies in the toolbox	
Chairpersons	Johannes Ott , <i>Austria</i> Eileen Manalo , <i>Philippines</i>	
08:30-08:45	Estetrol: Role in MHT/HRT? Johannes Ott , <i>Austria</i>	
08:45-08:50	Discussion	
08:50-09:05	Testosterone vs DHEA - which is the best option for androgen replacement? Andrea Genazzani , <i>Italy</i>	
09:05-09:10	Discussion	
09:10-09:25	Neurokinin targeted therapies - genuine alternatives to MHT? Nick Panay , <i>UK</i>	
09:25-09:30	Discussion	
09:30-10:00	Debate: Should all women in menopause be offered androgens? For: Andrea Genazzani , <i>Italy</i> Against: Mark Brincat , <i>Malta</i> Discussion	

10:00-10:30 *Coffee break, visit the exhibition and e-poster viewing*

10:30-12:00	INFERTILITY AND SURGERY	HALL C
Capsule	Exploring surgical advancements and alternatives in fertility care, highlighting the Balkan initiative for uterine transplantation, fertility-sparing procedures, prevention of endometriosis recurrence, and microwave ablation for uterine diseases	
Chairpersons	Athanasios Protopapas , <i>Greece</i> Grigoris F. Grimbizis , <i>Greece</i>	
10:30-10:50	Global overview of uterine transplantation and the Balkan initiative Elias Tsakos , <i>Greece</i>	
10:50-10:55	Discussion	
10:55-11:15	Fertility sparing surgery in gynecology Grigoris F. Grimbizis , <i>Greece</i>	
11:15-11:20	Discussion	
11:20-11:35	Endometriosis recurrence after surgery: Why it happens and how to prevent it Theodoros Theodoridis , <i>Greece</i>	
11:35-11:40	Discussion	
11:40-11:55	Microwave ablation for uterine diseases Xiaoming Gong , <i>China</i>	
11:55-12:00	Discussion	

12:00-12:05 *Change of session*

12:05-12:30	PLENARY SESSION	HALL A Streamed to Hall D & E
Capsule	Epigenetics and reprogramming research in infertility and in utero development focuses on how DNA methylation, histone modification, and RNA interact during gametogenesis, early embryogenesis and placentation, disruption of which causes infertility and pregnancy complications	
Chairpersons	Rene Frydman , <i>France</i> Mina Popovic , <i>Spain</i>	
12:05-12:25	Epigenetics and reprogramming David Monk , <i>UK</i>	
12:25-12:30	Discussion	

12:30-13:30 *Lunch break, visit the exhibition and e-poster viewing*

13:30-15:00	MENOPAUSE AND ENDOMETRIOSIS	HALL C
Capsule	Endometriosis, an estrogen dependent disease, develops mostly in women of reproductive age and usually regresses after menopause or ovariectomy. Postmenopausal women with endometriosis have the same chances of having menopausal symptoms, particularly hot flashes and night sweats as women without	

	endometriosis. Treatments depend on symptom severity and medical history. However, postmenopausal estrogen use may exacerbate endometriosis.
Chairpersons	Athanasios Protopapas , <i>Greece</i> Leonidas Zepeiridis , <i>Greece</i>
13:30-14:00	Debate: Hormone therapy in menopausal women with endometriosis
13:30	Yes: George L. Adonakis , <i>Greece</i>
13:40	No: Sophia Kalantaridou , <i>Greece</i>
13:50	Discussion
14:00-14:15	Management of osteoporosis in women with a history of endometriosis Panagiotis Anagnostis , <i>Greece</i>
14:15-14:20	Discussion
14:20-14:35	Natural progesterone versus artificial progestogens Johannes Ott , <i>Austria</i>
14:35-14:40	Discussion
14:40-14:55	Metabolomics as a tool for early detection of ectopic pregnancy Jose Horcajadas , <i>Spain</i>
14:55-15:00	Discussion
15:00-16:30	IMAGING IN GYNECOLOGY HALL C
Capsule	The debate is still ongoing - would MRI replace ultrasound and histological evaluation
Chairpersons	Matthaios Fraidakis , <i>Greece</i> Eileen Manalo , <i>Philippines</i>
15:00-15:25	Continuous reproductive identity: A new information architecture for reproductive medicine Jacques Kadoch , <i>Canada</i>
15:25-15:30	Discussion
15:30-15:55	Diagnosis of adenomyosis: Is ultrasound accurate enough to replace histology? Dimitrios Mavrelas , <i>UK</i>
15:55-16:00	Discussion
16:00-16:25	Ovarian tumors: How accurate is the prediction of histology with imaging? Katia Domali , <i>Greece</i>
16:25-16:30	Discussion

Saturday, November 14, 2026

Hall D – Fetomaternal Medicine

08:30-10:00		PRETERM DELIVERY	HALL D
Chairpersons		Gian Carlo Di Renzo, Italy George Daskalakis, Greece	
08:30-08:55		Debate: Once cerclage always cerclage? Evidence for prior pregnancy	
	08:30	Pro: Andrew Shennan, UK	
	08:35	Con: Austin Ugwumadu, UK	
	08:40	Discussion	
08:55-09:20		Debate: When to deliver in suspected chorioamnionitis during active labor? To perform immediate cesarean section?	
	08:55	Pro: Austin Ugwumadu, UK	
	09:00	Con: Howard Berger, Canada	
	09:05	Discussion	
09:20-09:35		Should prediction models and new biomarkers replace traditional risk factors in preterm birth screening? Dilli Anumba, UK	
09:35-10:00		Debate: Should we administer progesterone after arrested preterm labor after 24 weeks of gestation	
	09:35	Pro: Howard Berger, Canada	
	09:40	Con: Ioannis Tsakiridis, Greece	
	09:45	Discussion	

10:00-10:30 *Coffee break, visit the exhibition and e-poster viewing*

10:30-12:00		CONTROVERSIAL ISSUES IN LABOR AND DELIVERY	HALL D
Chairpersons		Apostolos Mamopoulos, Greece Jim Thornton, UK	
10:30-11:00		Debate: Induction of labor following a previous cesarean section	
	10:30	Pro: Yariv Yogev, Israel	
	10:40	Con: Jim Thornton, UK	
	10:50	Discussion	
11:00-11:30		Debate: Delivery in the extremely premature newborn. Cesarean section for all?	
	11:00	Pro: Austin Ugwumadu, UK	
	11:10	Con: Howard Berger, Canada	
	11:20	Discussion	
11:30-12:00		Debate: Different countries different medicine? In terms of cesarean section rate	
	11:30	Low CS rate: Eyal Sheiner, Israel	
	11:40	High CS rate: Asma Khalil, UK	
	11:50	Discussion	

12:00-12:05 *Change of session*

12:05-12:30		PLENARY SESSION	HALL A <i>Streamed to Hall D & E</i>
Capsule		Epigenetics and reprogramming research in infertility and in utero development focuses on how DNA methylation, histone modification, and RNA interact during gametogenesis, early embryogenesis and placentation, disruption of which causes infertility and pregnancy complications	
Chairpersons		Rene Frydman, France Mina Popovic, Spain	
12:05-12:25		Epigenetics and reprogramming David Monk, UK	
12:25-12:30		Discussion	

12:30-13:30 *Lunch break, visit the exhibition and e-poster viewing*

13:30-15:00	DIABETES AND OBESITY	HALL D
Chairpersons	Yariv Yogev, Israel Gerard Visser, Netherlands	
13:30-13:50	How do you know that your patient is well controlled? Yariv Yogev, Israel	
13:50-14:25	Debate: When to start pharmacological treatment? Should we use oral agents? Which?	
13:50	Pro: Gerard Visser, Netherlands	
14:00	Con: Rinat Gabbay-Benziv, Israel	
14:10	Discussion	
14:25-14:55	GLP-1 medications for GDM Rinat Gabbay-Benziv, Israel	
14:55-15:00	Discussion	

15:00-16:30	PANEL EXPERTS CASE DISCUSSION - DAILY DILEMMAS IN MODERN OBSTETRICS	HALL D
Chairpersons	Yariv Yogev, Israel Gerard Visser, Netherlands	
Discussants	Asma Khalil, UK Apostolos Athanasiadis, Greece Nir Melamed, Canada Gian Carlo Di Renzo, Italy Giuseppe Rizzo, Italy	
	1. Umbilical cord varix- IOL? What antenatal surveillance is recommended? 2. 28 weeks of gestation, breech presentation in active labor. To give or not to give MgSo4? Corticosteroids? 3. 3rd anatomy scan for all? 4. When do you recommend cesarean section for suspected macrosomia? 4000? 4250? 4500? 5000? 5. G1Po 39+2 weeks of gestation with normal pregnancy follow-up- Should we perform IOL by maternal request? 6. Should we perform once weekly/bi-weekly fetal surveillance in well-controlled GDM? 7. G1P0, 26 years old. Low risk pregnancy. Amniocentesis for all? NIPT? None? 8. Should obese women be induced at 39 weeks?	

Faculty Index

Adonakis, George L.	4, 8, 14	Mappa, Ilenia	2
Anagnostis, Panagiotis	8, 14	Mára, Michal	4
Anumba, Dilli	15	Mastenbroek, Sebastiaan	1, 2, 6
Asanidze, Elene	8	Mavrellos, Dimitrios	14
Athanasiadis, Apostolos	9, 10, 16	Melamed, Nir	9, 10, 16
Attali, Emmanuel	10	Messinis, Ioannis E.	12
Aviram, Amir	9, 10	Misrahi, Micheline	8
Bartolacci, Alessandro	5, 6, 11	Molinaro, Pietro	8
Ben Rafael, Zion	1, 2, 3, 11, 12	Monk, David	11, 13, 15, 21
Berger, Howard	10, 15	Moragianni, Vasiliki A.	1, 3
Brincat, Mark	7, 8, 13	Morman, Rachel	11
Broekmans, Frank	3, 12	Ombelet, Willem	4
Carmi, Shai	2, 6	Orvieto, Raoul	3
Cicinelli, Ettore	3, 4	Ott, Johannes	13, 14
Cobo, Ana	2, 5	Panay, Nick	7, 8, 13
Coticchio, Giovanni	5, 6	Papaleo, Enrico	1
Dafopoulos, Konstantinos	3, 12	Picton, Helen	5, 6
Dagklis, Themistoklis	10	Piltonen, Terhi	3, 5, 7, 9, 11, 19
Daniilidis, Angelos	4	Pirtea, Paul	3, 4, 12
Daskalakis, George	10, 15	Pistofidis, George	7
Di Renzo, Gian Carlo	9, 15, 16	Popovic, Mina	6, 11, 13, 15, 21
Dolmans, Marie-Madeleine	7	Protopapas, Athanasios	7, 13, 14
Domali, Katia	14	Racowsky, Catherine	1, 2, 6
Donnez, Jacques	1, 3, 7	Rienzi, Laura	1, 5, 6, 11
Fausser, Bart	1, 2, 3, 5, 7, 8, 9, 11, 19	Rizzo, Giuseppe	1, 2, 10, 16
Fraidakis, Matthaios	14	Santamaria, Xavier	3
Frydman, Rene	2, 11, 13, 15, 21	Sfontouris, Ioannis	5, 6
Gabbay-Benziv, Rinat	10, 16	Sheiner, Eyal	9, 15
Gallardo Molina, Miguel	5	Shennan, Andrew	9, 15
Genazzani, Andrea	13	Siristatidis, Charalampos	3
Gleicher, Norbert	2, 4, 11	Somigliana, Edgardo	1, 3, 4
Gong, Xiaoming	13	Tarlatzis, Basil	1, 4, 8, 11, 12
Goulis, Dimitrios	8, 10	Theodoridis, Theodoros	7, 13
Graziottin, Alessandra	7, 8	Thomakos, Nikolaos	10
Griffin, Darren	6	Thornton, Jim	15
Grimbizis, Grigoris F.	4, 7, 13	Tsakiridis, Ioannis	10, 15
Hanassab, Simon	3, 4	Tsakos, Elias	13
Hiersch, Liran	9, 10	Tsibizova, Valentina	2
Hirschberg, Angelica	7, 8	Ugwumadu, Austin	15
Horcajadas, Jose	14	van Rossum, Elisabeth	1
Kalantaridou, Sophia	14	Vassena, Rita	2, 5, 6, 12
Khalil, Asma	9, 10, 15, 16	Venetis, Christos	3, 11
Kolibianakis, Efstratios	3, 4	Visser, Gerard	10, 16
Konstantinidou, Anastasia	9	Vižintin, Zdenko	7
Lainas, George	6	Vlachos, Nikolaos	4
Laven, Joop	1, 3, 5, 7, 8, 9, 11, 19	Wainstock, Tamar	10
Loutradis, Dimitris	11	Williams, Zev	2
Makrakis, Evangelos	12	Yogev, Yariv	1, 9, 10, 15, 16
Makrigiannakis, Antonis	4	Zepeiridis, Leonidas	6
Mamopoulos, Apostolos	10, 15	Zepeiridis, Leonidas	14
Manalo, Eileen	7, 13, 14	Zikopoulos, Konstantinos	4

Oral Presentations

Thursday, November 12

13:00-14:30	ORAL PRESENTATION SESSION 1:	HALL E
-------------	------------------------------	--------

Chairpersons

13:00-13:07

13:07-13:14

13:14-13:21

13:21-13:28

13:28-13:35

13:35-13:42

13:42-13:49

13:49-13:56

13:56-14:03

14:03-14:10

14:10-14:17

14:17-14:24

14:30-15:30	ORAL PRESENTATION SESSION 2:	HALL C
-------------	------------------------------	--------

Chairpersons

14:30-14:37

14:37-14:44

14:44-14:51

14:51-14:58

14:58-15:05

15:05-15:12

15:12-15:19

15:19-15:26

14:30-15:30	ORAL PRESENTATION SESSION 3:	HALL E
-------------	------------------------------	--------

Chairpersons

14:30-14:37

14:37-14:44

14:44-14:51

14:51-14:58

14:58-15:05

15:05-15:12

15:12-15:19

15:19-15:26

15:30-16:00 *Coffee break*

16:00-17:00	ORAL PRESENTATION SESSION 4:	HALL C
-------------	------------------------------	--------

Chairpersons

16:00-16:07

16:07-16:14

16:14-16:21

16:21-16:28

16:28-16:35

16:35-16:42

16:42-16:49

16:49-16:56

16:00-17:00	ORAL PRESENTATION SESSION 5:	HALL E
-------------	------------------------------	--------

Chairpersons

16:00-16:07

16:07-16:14

16:14-16:21

16:21-16:28

16:28-16:35

16:35-16:42

16:42-16:49

16:49-16:56

17:00-18:30 ORAL PRESENTATION SESSION 6: HALL C

Chairpersons

17:00-17:07

17:07-17:14

17:14-17:21

17:21-17:28

17:28-17:35

17:35-17:42

17:42-17:49

17:49-17:56

17:56-18:03

18:03-18:10

18:10-18:17

18:17-18:24

19:30-20:30 Networking Reception in the exhibition area

Friday, November 13, 2026

10:30-12:00 ORAL PRESENTATION SESSION 7: HALL E

Chairpersons

10:30-10:37

10:37-10:44

10:44-10:51

10:51-10:58

10:58-11:05

11:05-11:12

11:12-11:19

11:19-11:26

11:26-11:33

11:33-11:40

11:40-11:47

11:47-11:54

12:00-12:05 Change of session

**12:05-12:30 PLENARY SESSION HALL A
Streamed to Hall D & E**

Capsule PCOS is the most common endocrinopathy that affect all phases of women's life

Chairpersons **Bart Fauser**, Netherlands

Joop Laven, Netherlands

12:05-12:25 PCOS in OBGYN (overview of PCO in reproductive life, menopause, pregnancy etc)

Terhi Piltonen, Finland

12:25-12:30 Discussion

12:30-12:35 Change of session

**12:35-13:35 INDUSTRY SUPPORTED SESSION HALL B
See page X**

**12:35-13:05 INDUSTRY SUPPORTED SESSION HALL C
See page X**

12:35-13:35 ORAL PRESENTATION SESSION 8: HALL E

Chairpersons

12:35-12:42

12:42-12:49

12:49-12:56

12:56-13:03

13:03-13:10
13:10-13:17
13:17-13:24
13:24-13:31

13:35-14:30 Lunch break, visit the exhibition and e-poster viewing

14:00-15:00	ORAL PRESENTATION SESSION 9:	HALL E
--------------------	-------------------------------------	---------------

Chairpersons

14:00-14:07
14:07-14:14
14:14-14:21
14:21-14:28
14:28-14:35
14:35-14:42
14:42-14:49
14:49-14:56

15:30-15:35 Change of session

15:35-17:00	ORAL PRESENTATION SESSION 10:	HALL E
--------------------	--------------------------------------	---------------

Chairpersons

15:35-15:42
15:42-15:49
15:49-15:56
15:56-16:03
16:03-16:10
16:10-16:17
16:17-16:24
16:24-16:31
16:31-16:38
16:38-16:45
16:45-16:52
16:52-16:59

17:00-17:20 Coffee break, visit the exhibition and e-poster viewing

17:20-18:30	ORAL PRESENTATION SESSION 11:	HALL E
--------------------	--------------------------------------	---------------

Chairpersons

17:20-17:27
17:27-17:34
17:34-17:41
17:41-17:48
17:48-17:55
17:55-18:02
18:02-18:09
18:09-18:16
18:16-18:23
18:23-18:30

Saturday, November 14, 2026

08:30-10:00	ORAL PRESENTATION SESSION 12:	HALL B
--------------------	--------------------------------------	---------------

Chairpersons

08:30-08:37
08:37-08:44
08:44-08:51
08:51-08:58
08:58-09:05
09:05-09:12
09:12-09:19
09:19-09:26
09:26-09:33
09:33-09:40
09:40-09:47
09:47-09:54

10:00-10:30 Coffee break, visit the exhibition and e-poster viewing

10:30-12:00	ORAL PRESENTATION SESSION 13:	HALL B
--------------------	--------------------------------------	---------------

Chairpersons

10:30-10:37
10:37-10:44
10:44-10:51
10:51-10:58
10:58-11:05
11:05-11:12
11:12-11:19
11:19-11:26
11:26-11:33
11:33-11:40
11:40-11:47
11:47-11:54

12:00-12:05 Change of session

12:05-12:30	PLENARY SESSION	HALL A <i>Streamed to Hall D & E</i>
--------------------	------------------------	--

Capsule Epigenetics and reprogramming research in infertility and in utero development focuses on how DNA methylation, histone modification, and RNA interact during gametogenesis, early embryogenesis and placentation, disruption of which causes infertility and pregnancy complications

Chairpersons **Rene Frydman**, France
Mina Popovic, Spain

12:05-12:25	Epigenetics and reprogramming David Monk , UK
12:25-12:30	Discussion

12:30-13:30 Lunch break, visit the exhibition and e-poster viewing

10:30-12:00	ORAL PRESENTATION SESSION 14:	HALL E
--------------------	--------------------------------------	---------------

Chairpersons

10:30-10:37
10:37-10:44
10:44-10:51
10:51-10:58
10:58-11:05
11:05-11:12
11:12-11:19
11:19-11:26
11:26-11:33
11:33-11:40
11:40-11:47

11:47-11:54

13:30-15:00	ORAL PRESENTATION SESSION 15:	HALL B
--------------------	--------------------------------------	---------------

Chairpersons

13:30-13:37
13:37-13:44
13:44-13:51
13:51-13:58
13:58-14:05
14:05-14:12
14:12-14:19
14:19-14:26
14:26-14:33
14:33-14:40
14:40-14:47
14:47-14:54

13:30-15:00	ORAL PRESENTATION SESSION 16:	HALL E
--------------------	--------------------------------------	---------------

Chairpersons

13:30-13:37
13:37-13:44
13:44-13:51
13:51-13:58
13:58-14:05
14:05-14:12
14:12-14:19
14:19-14:26
14:26-14:33
14:33-14:40
14:40-14:47
14:47-14:54

15:00-16:30	ORAL PRESENTATION SESSION 17:	HALL B
--------------------	--------------------------------------	---------------

Chairpersons

15:00-15:07
15:07-15:14
15:14-15:21
15:21-15:28
15:28-15:35
15:35-15:42
15:42-15:49
15:49-15:56
15:56-16:03
16:03-16:10
16:10-16:17
16:17-16:24

15:00-16:30	ORAL PRESENTATION SESSION 18:	HALL E
--------------------	--------------------------------------	---------------

Chairpersons

15:00-15:07
15:07-15:14
15:14-15:21
15:21-15:28
15:28-15:35
15:35-15:42
15:42-15:49
15:49-15:56
15:56-16:03
16:03-16:10
16:10-16:17
16:17-16:24

Moderated e-Posters

Thursday, November 12, 2026

17:00-18:30	MODERATED E-POSTER SESSION 1:	HALL E
Chairpersons		
17:00-17:04		
17:04-17:08		
17:08-17:12		
17:12-17:16		
17:16-17:20		
17:20-17:24		
17:24-17:28		
17:28-17:32		
17:32-17:36		
17:36-17:40		
17:40-17:44		
17:44-17:48		
17:48-17:52		
17:52-17:56		
17:56-18:00		
18:00-18:04		
18:04-18:08		
18:08-18:12		
18:12-18:16		
18:16-18:20		
18:20-18:24		
18:24-18:28		

Friday, November 13, 2026

08:30-10:00	MODERATED E-POSTERS SESSION 2:	HALL E
Chairpersons		
08:30-08:34		
08:34-08:38		
08:38-08:42		
08:42-08:46		
08:46-08:50		
08:50-08:54		
08:54-08:58		
08:58-09:02		
09:02-09:06		
09:06-09:10		
09:10-09:14		
09:14-09:18		
09:18-09:22		
09:22-09:26		
09:26-09:30		
09:30-09:34		
09:34-09:38		
09:38-09:42		
09:42-09:46		
09:46-09:50		
09:50-09:54		
09:54-09:58		

Saturday, November 14, 2026

08:30-10:00	MODERATED E-POSTERS SESSION 3:	HALL E
Chairpersons		
08:30-08:34		
08:34-08:38		
08:38-08:42		
08:42-08:46		
08:46-08:50		
08:50-08:54		

08:54-08:58
08:58-09:02
09:02-09:06
09:06-09:10
09:10-09:14
09:14-09:18
09:18-09:22
09:22-09:26
09:26-09:30
09:30-09:34
09:34-09:38
09:38-09:42
09:42-09:46
09:46-09:50
09:50-09:54
09:54-09:58

Industry Supported Sessions

Friday, November 13, 2026

12:35-13:35	TBA	HALL B
-------------	-----	--------

Supported by



GEDEON RICHTER

12:35-13:05	Hybrid Cooperative Complexes (HCC) of hyaluronic acid for WA treatment: from clinical trials to real-world case discussions	HALL C
-------------	---	--------

Supported by



Caring Innovation

Speakers:

Teresa Aznar Altaba, *Spain*

Francesco Meani, *Switzerland*